POTOMAC, MARYLAND, September 9, 2025 – IGC Pharma, Inc. (NYSE American: IGC), a clinical-stage pharmaceutical company focused on therapies for Alzheimer’s disease, today announced that its Artificial Intelligence (AI) team
POTOMAC, MD, September 02, 2025 / IGC Pharma, Inc. (NYSE American: IGC) today announced expansion of its ongoing Phase 2 clinical trial evaluating IGC-AD1, a novel investigational treatment for agitation in
POTOMAC, MARYLAND, August 28, 2025 / IGC Pharma, Inc. (NYSE American: IGC) today announced that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for
POTOMAC, MARYLAND, August 27, 2025 / IGC Pharma, Inc. (NYSE American: IGC) today announced that Ascendiant Capital Markets has issued a coverage report entitled: “Reports Q1 results. We believe more positive
POTOMAC, MD, August 25, 2025 / IGC Pharma, Inc. (NYSE American: IGC) today announced the expansion of its ongoing Phase 2 clinical trial evaluating IGC-AD1, an investigational drug candidate for treating
POTOMAC, MARYLAND – August 19, 2025 – IGC Pharma, Inc. (“IGC” or the “Company”) (NYSE American: IGC), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer’s disease,
POTOMAC, MARYLAND – August 05, 2025 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage pharmaceutical company leveraging AI to develop innovative treatments for Alzheimer’s and
– Company to showcase innovations in AI-driven drug discovery and early disease detection, including solutions for low resource settings –
POTOMAC, MARYLAND – July 21, 2025 – IGC Pharma, Inc. (NYSE American: IGC) a clinical-stage biopharmaceutical company focused on Alzheimer’s disease, today announced that its Principal Scientist, Jagadeesh Rao, Ph.D.,
Multimodal foundation model enables personalized cognitive forecasts and expands access to Alzheimer’s diagnostics